journal contribution
posted on 2023-04-03, 23:22 authored by Tatjana Bilich, Malte Roerden, Yacine Maringer, Annika Nelde, Jonas S. Heitmann, Marissa L. Dubbelaar, Andreas Peter, Sebastian Hörber, Jens Bauer, Jonas Rieth, Marcel Wacker, Fiamma Berner, Lukas Flatz, Stefanie Held, Peter Brossart, Melanie Märklin, Philipp Wagner, Eva Erne, Reinhild Klein, Hans-Georg Rammensee, Helmut R. Salih, Juliane S. Walz <p>Supplementary Figures S1-S5 Supplementary Tables S1-S3 revised</p>
Funding
Bundesministerium für Bildung und Forschung
Deutsche Forschungsgemeinschaft
German Research Foundation
Deutsche Forschungsgemeinschaft under Germany's Excellence Strategy
Wilhelm Sander Stiftung
José Carreras Leukämie-Stiftung
Fortüne Program of the University of Tübingen
History
ARTICLE ABSTRACT
Patients with cancer, in particular patients with hematologic malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4+ and CD8+ T-cell responses in unexposed and SARS-CoV-2–infected patients with cancer to characterize SARS-CoV-2 immunity and to identify immunologic parameters contributing to COVID-19 outcome. Unexposed patients with hematologic malignancies presented with reduced prevalence of preexisting SARS-CoV-2 cross-reactive CD4+ T-cell responses and signs of T-cell exhaustion compared with patients with solid tumors and healthy volunteers. Whereas SARS-CoV-2 antibody responses did not differ between patients with COVID-19 and cancer and healthy volunteers, intensity, expandability, and diversity of SARS-CoV-2 T-cell responses were profoundly reduced in patients with cancer, and the latter associated with a severe course of COVID-19. This identifies impaired SARS-CoV-2 T-cell immunity as a potential determinant for dismal outcome of COVID-19 in patients with cancer.
This first comprehensive analysis of SARS-CoV-2 immune responses in patients with cancer reports on the potential implications of impaired SARS-CoV-2 T-cell responses for understanding pathophysiology and predicting severity of COVID-19, which in turn might allow for the development of therapeutic measures and vaccines for this vulnerable patient population.See related commentary by Salomé and Horowitz, p. 1877.This article is highlighted in the In This Issue feature, p. 1861
